Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 35912183)

  • 1. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.
    Xie W; Huang H; Xiao S; Fan Y; Deng X; Zhang Z
    Autoimmun Rev; 2020 Dec; 19(12):102687. PubMed ID: 33131688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
    Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
    Liu X; Li S; Ke L; Cui H
    BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.
    Lopez-Olivo MA; Kachira JJ; Abdel-Wahab N; Pundole X; Aldrich JD; Carey P; Khan M; Geng Y; Pratt G; Suarez-Almazor ME
    Eur J Cancer; 2024 May; 207():114148. PubMed ID: 38834015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer.
    Aung WY; Lee CS; Morales J; Rahman H; Seetharamu N
    Clin Lung Cancer; 2023 Nov; 24(7):598-612. PubMed ID: 37328320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
    Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review.
    Machado AP; Ratliff H; Abdelwahab A; Vohra MH; Kuang A; Shatila M; Khan MA; Shafi MA; Thomas AS; Philpott J; Alhalabi O; Wang Y
    J Cancer; 2023; 14(16):2956-2963. PubMed ID: 37859810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.